What does Sensei Biotherapeutics do?

Sensei Biotherapeutics (NASDAQ:SNSE) is a biopharmaceutical company focused on the development of next-generation immunotherapies for cancer and infectious diseases. The company's work revolves around its proprietary ImmunoPhage™ platform and its novel monoclonal antibody and T-cell receptor discovery platform, aimed at tailoring treatments to harness the body's immune system more effectively. Their pipeline includes multiple projects in various stages of research and clinical development, designed to achieve better outcomes for patients with unmet medical needs. Sensei Biotherapeutics is on a mission to transform cancer treatment paradigms and improve patient lives through groundbreaking scientific innovation.
Sensei Biotherapeutics company media

Company Snapshot

key

Ownership

Public
people

Employees

27
pie chart

Sector

Health Care
location pin

Head Office

Rockville, United States
founded flag

Year Founded

1999

What does Sensei Biotherapeutics specialise in?

/Cancer Therapies /Immuno-Pharmacotherapy /Biotechnology Research /Pharmaceutical Development /Biopharmaceutical Manufacturing /Clinical Trials

What are the products and/or services of Sensei Biotherapeutics?

Overview of Sensei Biotherapeutics offerings
Immuno-oncology therapeutics harnessing the immune system to fight cancer, focusing on novel treatments for various tumor types.
VISTA checkpoint inhibitors targeting the V-set immunoregulatory domain to augment cancer immunotherapy efficacy.
Precision medicine approach, using genomic data to tailor unique treatment strategies for cancer patients.
Research on bacteriophage-based vaccines aimed at stimulating the immune system against cancer.
Pipeline of monoclonal antibodies designed for specific tumor-associated antigens, improving targeted therapy options.
Collaborative research partnerships with academic institutions and biotech firms to speed up the development of innovative cancer treatments.

Who is in the executive team of Sensei Biotherapeutics?

Sensei Biotherapeutics leadership team
  • Photo of Mr. John K. Celebi M.B.A.
    Mr. John K. Celebi M.B.A.
    President, CEO & Director
  • Photo of Dr. Edward Van der Horst Ph.D.
    Dr. Edward Van der Horst Ph.D.
    Chief Scientific Officer
  • Photo of Mr. Josiah Craver
    Mr. Josiah Craver
    Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer
  • Photo of Ms. Lora Pike
    Ms. Lora Pike
    Vice President of Investor Relations & Communications
  • Photo of Mr. Christopher W. Gerry J.D.
    Mr. Christopher W. Gerry J.D.
    Senior VP, General Counsel & Secretary
  • Photo of Ms. Stephanie Krebs M.B.A., M.S.
    Ms. Stephanie Krebs M.B.A., M.S.
    Chief Business Officer
  • Photo of Dr. Aaron Weitzman FACP, M.D., Ph.D.
    Dr. Aaron Weitzman FACP, M.D., Ph.D.
    Chief Medical Officer